Variant · Expression
NR4A2 Overexpression
CI-VAR-00003249Explore in graph →CIViC 5323
Curated evidence
Evidence by cancer (3 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 35582016
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Pancreatic Ductal Adenocarcinoma2 | ||||||||
| NR4A2 Overexpression | C-DIM 12 + GemcitabineCombination | Predictive | D | Supports Resistance | 3 | submitted | EID12649In pancreatic cancer cell lines MiaPaCa2 and Panc1, gemcitabine 1 μmol/L induced NR4A2/NURR1 expression and triggered cytoprotective autophagy, while both CRISPR-mediated NR4A2 knockout and the NR4A2 … (full text at CIViC) PMID 35582016 · Zarei et al., 2021 · Open in CIViC | civic |
| NR4A2 Overexpression OR ATG7 Overexpression OR ATG12 Overexpression | (prognostic) | Prognostic | B | Supports Poor Outcome | 3 | submitted | EID12650In a retrospective TCGA PDAC (tumors n = 179, normals n = 171), high ATG7 expression was significantly associated with poorer survival on Kaplan–Meier analysis (P = 0.013), and high ATG12 expression s… (full text at CIViC) PMID 35582016 · | |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available